Company Focus
GSK
Latest GSK News
Biotechnology
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has voted against two proposed combination regimens containing GSK’s Blenrep (belantamab mafodotin), sending shares in the UK drugmaker tumbling by 5% Friday. 18 July 2025
Related News
Insights
Company Spotlight
A clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
Latest News & Features of interest to GSK
Pharmaceutical
Danish allergy immunotherapy specialist ALK has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy 2 mg for anaphylaxis treatment of adults and children (≥30 kg). 18 July 2025
Biotechnology
German mRNA specialist BioNTech has announced that Ryan Richardson will step down from his position as chief strategy officer and member of the management board. 18 July 2025
Biotechnology
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has voted against two proposed combination regimens containing GSK’s Blenrep (belantamab mafodotin), sending shares in the UK drugmaker tumbling by 5% Friday. 18 July 2025
Biotechnology
US biotech TRIO Pharmaceuticals has announced the appointment of Patrick Doyle as chief executive (CEO effective immediately. 18 July 2025
Biotechnology
Scottish biotech Trogenix has announced two senior appointments as the company advances its pipeline towards the clinic. 18 July 2025
Biotechnology
US precision immune-oncology firm I-Mab has entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech. 18 July 2025
Pharmaceutical
Once seen as a niche tool for rare tumors, theranostics is quickly becoming a new standard in cancer care. Combining diagnostics and therapy in a single platform, the field has drawn billions in pharma investment and sparked regulatory momentum, as precision imaging begins to guide not only what patients receive—but when, how often, and with what expected impact. 18 July 2025
Biotechnology
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
Biotechnology
US companies SandboxAQ and iOncologi have announced a strategic collaboration to jointly develop, validate, and commercialize a novel high-fidelity mRNA vaccine for glioblastoma, the most common and aggressive malignant brain tumor in adults. 17 July 2025
Biotechnology
Swiss pharma giant Roche has won approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for its combination treatment of Columvi (glofitamab) alongside gemcitabine and oxaliplatin (GemOx) for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant. 17 July 2025
Latest In Brief for GSK
Pharmaceutical
Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with prednisone or prednisolone for the treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) and homologous recombination repair (HRR) gene alterations. 3 July 2025
Latest Relevant Ones To Watch News
US precision immune-oncology firm I-Mab has entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech. 18 July 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze